99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
July 2024 in “Journal of Investigative Dermatology” Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
7 citations
,
November 2018 in “British Journal of Dermatology” Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
80 citations
,
April 2018 in “Trends in Molecular Medicine” Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
74 citations
,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
64 citations
,
July 2016 in “Journal of Immunology” Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
June 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” ILC1-like cells can cause alopecia areata by attacking hair follicles.
A teenager had both alopecia areata and vitiligo, which are rare to occur together.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
6 citations
,
June 2016 in “Experimental Dermatology” Frontal Fibrosing Alopecia is a poorly understood condition that is hard to treat and causes distressing hair loss.
3 citations
,
January 2015 in “Nasza Dermatologia Online” Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
1 citations
,
May 2017 in “InTech eBooks” The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.